The AgResults Foot and Mouth Disease (FMD) Vaccine Challenge Project is an eight-year, US$17.68 million prize competition that supports the development and uptake of high-quality FMD vaccines tailored to meet the needs of Eastern Africa, targeting in particular: Burundi, Ethiopia, Kenya, Rwanda, Tanzania and Uganda. The prize is structured as a cost-share that reduces the cost-per-dose for buyers, enabling public and private sector actors to better combat FMD through more consistent purchases of the new vaccines. This will also increase the market potential for vaccines in the region. GALVmed serves as the Project Manager for this competition.
FMD is a viral disease of livestock that affects cattle, swine, sheep, goats and other cloven-hoofed ruminants. The FMD virus is highly contagious, and outbreaks of the disease can have severe economic consequences due to decreased livestock productivity and disruption of regional and international trade of animals and animal products. Africa loses about US$2.3bn annually due to FMD, with most of the economic burden falling on sub-Saharan Africa. FMD is estimated to circulate in 77% of the global livestock population, according to the OIE. Morbidity levels are very high, reaching 100% in susceptible populations, while mortality is generally low in adult animals. In Eastern Africa, where FMD is endemic, outbreaks typically strike as waves of infection one to two years apart with outbreaks exacerbated when multiple serotypes or strains circulate concurrently.
The following video explores the impact of Foot and Mouth Disease in Eastern Africa, from the perspective of both the small-scale livestock producers whose livestock and livelihoods are affected, as well as those who seek to control the disease on the ground and through policy development.
In order to meet the needs in Eastern Africa, AgResults is looking for animal health companies with experience in the development and commercialisation of FMD vaccines to develop and register vaccines that are safe, efficacious and viable for use against the currently circulating strains of the four serotypes of FMD in the region’s cattle. Vaccines registered in at least two of the AgResults target countries that meet all the requirements set out in the Target Product Profile will be eligible to participate in this cost-share initiative. This will provide an incentive to both public and private sector buyers in the region to purchase vaccines as part of a disease control strategy.
Full details of the Target Product Profile requirements can be found in the Competition Rules section (Annex 1) of the Request For Applications.
To support the adoption of new high-quality vaccines in the region, AgResults has established a cost-share mechanism which will reduce the cost-per-dose for both public and private sector buyers. Each year, AgResults commits to funding a portion of the purchase price of the vaccine for a specified volume of vaccine doses. AgResults provides funding directly to vaccine manufacturers, on behalf of the buyers. The cost-share will be available for 4.5 years after the first eligible vaccine is approved by the Project’s Judging Panel. The volume of doses eligible for the cost-share benefit will gradually increase over the four-year period, from 2 million doses in Year 1 to 5 million in Year 4, while the level of cost-share support will gradually decrease, to help buyers prepare for price adjustments that will occur after the project has closed.
Annual Level of Cost-Share Support
Volume of Doses Eligible for Cost-Share
Each year, AgResults will set aside specified allocations of the total available vaccine doses for use by the individual target countries (Country Reserves) based on: a) countries in which Marketing Authorisation for the new vaccine(s) is expected; b) each of above country’s share of the Region’s cattle population; and c) discussions with each country’s government. There will also be an annual Regional Pool open to buyers from all countries, which provides support in the form of additional cost-share doses beyond what is allocated through the Country Reserves. The chart below illustrates the annual split of aggregated Country Reserve and Regional Pool allocations (i.e. Year 1: 1.3M cost-share doses in Country Reserves and 0.7M cost-share doses in Regional Pool).
Annual Split of Country Reserve and Regional Pool allocations